Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference
09 sept. 2021 11h46 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients
08 sept. 2021 06h00 HE
|
GNT Pharma Co., Ltd
PIII Study for 496 ischemic stroke patients treated with endovascular thrombectomyFirst multi-target neuroprotectant for the intervention of ischemic brain injurySafety and efficacy verified in two...
Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
07 sept. 2021 07h30 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy
23 juin 2021 09h00 HE
|
RapidPulse, Inc
MIAMI, June 23, 2021 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15...
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
17 juin 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all...
The Worldwide Neurovascular Devices/Interventional Neurology Industry is Expected to Reach $3.8 Billion by 2026 at a CAGR of 8.6% from 2021
10 juin 2021 05h53 HE
|
Research and Markets
Dublin, June 10, 2021 (GLOBE NEWSWIRE) -- The "Global Neurovascular Devices/Interventional Neurology Market by Product (Embolization (Coil, Flow Diverter), Stents, Balloon Occlusion Devices, Clot...
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
27 mai 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an...
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
17 mai 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received...
Insights on the Intracranial Aneurysm Global Market to 2025 - Competitive Analysis and the Impact of COVID-19
21 avr. 2021 06h33 HE
|
Research and Markets
Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Global Intracranial Aneurysm Market (2020-2025) by Type, Condition, Treatment Type, End-User, Geography, Competitive Analysis and the Impact of...
NovaSignal Launches Platform To Transform Cerebral Blood Flow Measurement
14 avr. 2021 09h06 HE
|
NovaSignal Corporation
LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, today launched the NovaGuide™ 2 Platform that...